Sugi Predict

Sugi Predict / Compounds / SCHEMBL615143

SCHEMBL615143

SCHEMBL615143

CCN(CC)C(=O)Cc1nc2ccc(NS(=O)(=O)c3cccc(Cl)c3C)cc2s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 3/20 0.58
▸ HSD17B1 P14061 1/20 0.58
▸ HSD17B2 P37059 1/20 0.58
▸ ALDH1A1 P00352 5/20 0.50
▸ LMNA P02545 5/20 0.50
▸ MEN1 O00255 3/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ HPGD P15428 2/20 0.50
▸ THRB P10828 1/20 0.50
▸ PKM P14618 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ HTT P42858 5/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ FSCN1 Q16658 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ PPARG P37231 3/20 0.41
▸ PPARD Q03181 3/20 0.41
▸ PPARA Q07869 3/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL615802 0.85 ALDH1A1 (0.57) HSD11B1HSD17B1HSD17B2ALDH1A1LMNA
SCHEMBL618832 0.81 LMNA (0.55) HSD11B1HSD17B1HSD17B2ALDH1A1LMNA
SCHEMBL614858 0.80 LMNA (0.60) HSD11B1ALDH1A1LMNAMEN1KMT2A
SCHEMBL617123 0.80 LMNA (0.62) HSD11B1ALDH1A1LMNAMEN1KMT2A
SCHEMBL617881 0.80 LMNA (0.62) HSD11B1ALDH1A1LMNAMEN1KMT2A
SCHEMBL5832085 0.78 HSD11B1 (0.68) HSD11B1HSD17B1HSD17B2MEN1KMT2A
SCHEMBL617473 0.78 LMNA (0.66) HSD11B1ALDH1A1LMNAMEN1KMT2A
SCHEMBL615962 0.77 TP53 (0.59) ALDH1A1LMNAMEN1KMT2AHPGD
SCHEMBL3926760 0.74 HSD11B1 (1.00) HSD11B1HSD17B1HSD17B2PKMMAPT
SCHEMBL615039 0.74 PKM (0.49) HSD11B1HSD17B1HSD17B2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 — — US disclosed
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 — — US disclosed
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 — — US disclosed
US-20110009448-A1 Compound STERIX LIMITED 2011-01-13 — — US disclosed
US-20110009448-A1 Compound STERIX LIMITED 2011-01-13 — — US disclosed
US-20110009448-A1 Compound STERIX LIMITED 2011-01-13 — — US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 — — US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 — — US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 — — US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 — — US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 — — US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 — — US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 — — US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 — — US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 — — US disclosed
EP-1556040-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 Sterix Limited (GB) 2005-07-27 — — EP disclosed
US-20040143124-A1 Compound STERIX LIMITED (GB) 2004-07-22 — — US disclosed
WO-2004037251-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 STERIX LIMITED (GB) 2004-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer HSD11B1, HSD3B1, HSD11B2 HSD11B1 1/4885HSD17B1 5/4885HSD17B2 9/4885
US-20110009448-A1 Compound NR4A1, GPR6, PRMT6 HSD11B1 331/4885HSD17B1 616/4885HSD17B2 533/4885
US-20120041207-A1 Compound NR4A1, GPR6, PRMT6 HSD11B1 331/4885HSD17B1 616/4885HSD17B2 533/4885
US-20040143124-A1 Compound NR4A1, CBR1, NR2C2 HSD11B1 192/4885HSD17B1 461/4885HSD17B2 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.